A Single Gut Bacterium Reduced Lupus Markers in Animals. Could It Become a Probiotic Treatment?

A research team at UT San Antonio has identified what may be the first probiotic candidate for lupus: a common gut bacterium called Faecalibacterium prausnitzii that is consistently depleted in patients with the disease. When scientists restored the bacterium in animal models, lupus markers dropped significantly, and immune regulation partially recovered. The study, published April 13 in Nature Communications, is preliminary and has not yet been tested in humans, but it opens a genuinely new direction for a disease that has frustrated researchers for decades.

F. prausnitzii Depletion Found Consistently in Lupus Patients

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system attacks the body's own tissues, causing inflammation in the joints, kidneys, skin, heart, and lungs. Roughly 1.5 million Americans live with the condition, while global lupus prevalence sits at an estimated 43.7 per 100,000 persons, or about 3.41 million people worldwide. The disease disproportionately strikes young women and certain ethnic groups.

For years, researchers have noticed that the gut microbiome of lupus patients looks distinctly different from that of healthy people. Meta-analyses of gut microbiota in SLE show decreased microbial diversity and altered bacterial abundances across multiple studies, suggesting the imbalance is not incidental but mechanistically linked to the disease. What scientists lacked was a specific bacterial target. Dr. Laurence Morel and Dr. Yong Ge, both at UT San Antonio's Joe R. and Teresa Lozano Long School of Medicine, zeroed in on F. prausnitzii as the most consistently depleted species.

Why Restoring This Bacterium Could Reshape Lupus Treatment

The stakes are high because current lupus treatments are blunt instruments. Immunosuppressants and steroids manage symptoms but carry serious side effects: weight gain, swelling, cardiovascular complications, and sharply increased susceptibility to infection. Infection, in turn, is a leading cause of death among lupus patients. A probiotic that modulates immunity from the gut would sidestep many of those risks if it works in humans.

F. prausnitzii earns its relevance through butyrate, a short-chain fatty acid the bacterium produces when it digests dietary fiber. Butyrate is the primary energy source for cells lining the colon and helps maintain the mucin barrier that separates the gut contents from the rest of the body. When F. prausnitzii is scarce, fiber fermentation drops, butyrate levels fall, and the mucin lining weakens. As Dr. Ge put it: "If you have less bacteria digesting that fiber, you have less short chain fatty acids and a more pro-inflammatory condition." Research on gut microbiota dysbiosis in SLE confirms that this kind of impaired intestinal barrier function feeds immune dysregulation, altering cytokine production and driving abnormal T and B cell activity.

Animal Models Show Significant Reduction in Lupus Disease Markers

The UT San Antonio team tested F. prausnitzii supplementation directly in lupus animal models. The results were encouraging: supplementation significantly reduced markers of lupus, produced positive effects on both the kidneys and spleen, and partially restored immune regulation. The bacterium also shifted the broader microbiome, promoting more fiber digestion and less mucin degradation, which points to a systemic gut-health improvement rather than a single isolated effect.

Dr. Morel framed the significance plainly: "This is the first time in lupus research that we have identified a bacterium that is depleted and when returned, it helps." Prior work by Dr. Ge had already established F. prausnitzii's role in enhancing dietary fiber digestion in healthy conditions, which gave the team a mechanistic foothold before they began the lupus-specific work.

It is worth noting that probiotic effects are highly strain-specific. Earlier trials using Lactobacillus rhamnosus and Bifidobacterium bifidum showed no benefit for lupus patients, which underscores that identifying the right organism matters. A recent systematic review of probiotic supplementation across autoimmune diseases found reductions in inflammatory markers including IL-6 and TNF-alpha in some conditions, but results vary considerably by strain and disease context.

Key Hurdles Before F. prausnitzii Becomes a Clinical Option

Several obstacles stand between these animal results and a viable human treatment. Most practically, F. prausnitzii is extremely sensitive to oxygen and degrades quickly outside the gut, which means maintaining therapeutic levels would likely require frequent dosing. The mechanisms by which it exerts its effects are not yet fully understood, and the team has not yet identified which specific metabolites are driving immune protection versus inflammation reduction.

Human trials have not begun. The researchers acknowledge that further investigation is needed to confirm benefits in people and to determine optimal dosing, timing, and delivery. SLE's clinical complexity adds another layer: the disease varies widely between patients, and a treatment that works across that heterogeneity would be a significant achievement.

Next Steps: Diet, Metabolomics, and Personalized Microbiome Therapies

The UT San Antonio team plans to extend the work in several directions. They intend to investigate the metabolites associated with immune protection and inflammation more precisely, and to design studies examining the interplay between diet, the microbiome, and the immune system. Integrative tools like metagenomics and metabolomics are on the table for identifying microbial signatures that could support more personalized treatment strategies.

This work fits into a broader moment in lupus research. The Investigate Dietary Approaches for Lupus (IDEAL) initiative is separately exploring how diet and gut microbiome composition influence disease activity, and newer biological therapies for lupus such as belimumab and anifrolumab are generating clinical trial activity. A probiotic approach would not replace those drugs, but it could eventually complement them, or serve patients who cannot tolerate immunosuppression.

Dr. Ge's summary captures both the excitement and the appropriate humility: "We were very excited that a single probiotic strain could do such big things." The caveat is that those big things have so far only been demonstrated in animals. The next few years of research will determine whether F. prausnitzii can do them in people too.

Evidence rating

INVESTIGATIONAL — 71/100

Caveats:

• All efficacy data come from animal models only — no human clinical trials have been conducted yet.
• The exact mechanisms by which F. prausnitzii reduces lupus markers are not yet fully understood.
• F. prausnitzii is highly oxygen-sensitive and degrades rapidly, posing practical challenges for probiotic formulation.
• Funding source was not disclosed in the available reporting.

Published in Nature Communications, this study is based on animal model data only and has not yet been tested in human clinical trials. It identifies a specific mechanism — F. prausnitzii depletion reducing butyrate production and disrupting gut barrier integrity — but results in animal models do not reliably predict human outcomes. Independent replication in humans is needed before clinical conclusions can be drawn.

References

1. (2026). First potential probiotic treatment for lupus identified at UT San Antonio. https://news.uthscsa.edu/first-potential-probiotic-treatment-for-lupus-identified-at-ut-san-antonio/
2. Jingru Tian, Dingyao Zhang, Xu Yao, Yaqing Huang, Qianjin Lu (2023). Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ard-2022-223035
3. Shate Xiang, Yiqian Qu, Suhai Qian, et al. (2022). Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis. Lupus Science & Medicine. https://doi.org/10.1136/lupus-2021-000599
4. Quanren Pan, Fengbiao Guo, Yanyan Huang, et al. (2021). Gut Microbiota Dysbiosis in Systemic Lupus Erythematosus: Novel Insights into Mechanisms and Promising Therapeutic Strategies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.799788
5. Yuan-Yow Chiou, Tsu-Yun Chiu, Mei-Ju Chen (2026). Effect of Probiotic and Synbiotic Oral Supplementation in Autoimmune Diseases: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. https://doi.org/10.3390/nu18071107
6. Current treatment of systemic lupus erythematosus: a clinician's perspective – PMC. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226305/